<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Landing Page Article</title>
    <!-- BS CSS Stylesheet -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet"
        integrity="sha384-4bw+/aepP/YC94hEpVNVgiZdgIC5+VKNBQNGCHeKRQN+PtmoHDEXuppvnDJzQIu9" crossorigin="anonymous">
    <link rel="stylesheet" href="style.css">
    <!-- BS JS Stylesheet -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js"
        integrity="sha384-MrcW6ZMFYlzcLA8Nl+NtUVF0sA7MsXsP1UyJoMp4YLEuNSfAP+JcXn/tWtIaxVXM" crossorigin="anonymous"
        defer></script>

</head>

<body>
    <nav class="navbar navbar-expand-md bg-dark">
        <div class="container navbar-dark">
            <a href="index.html" class="navbar-brand"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20"
                    fill="currentColor" class="bi bi-virus" viewBox="0 0 16 16">
                    <path
                        d="M8 0a1 1 0 0 1 1 1v1.402c0 .511.677.693.933.25l.7-1.214a1 1 0 0 1 1.733 1l-.701 1.214c-.256.443.24.939.683.683l1.214-.701a1 1 0 0 1 1 1.732l-1.214.701c-.443.256-.262.933.25.933H15a1 1 0 1 1 0 2h-1.402c-.512 0-.693.677-.25.933l1.214.701a1 1 0 1 1-1 1.732l-1.214-.7c-.443-.257-.939.24-.683.682l.701 1.214a1 1 0 1 1-1.732 1l-.701-1.214c-.256-.443-.933-.262-.933.25V15a1 1 0 1 1-2 0v-1.402c0-.512-.677-.693-.933-.25l-.701 1.214a1 1 0 0 1-1.732-1l.7-1.214c.257-.443-.24-.939-.682-.683l-1.214.701a1 1 0 1 1-1-1.732l1.214-.701c.443-.256.261-.933-.25-.933H1a1 1 0 1 1 0-2h1.402c.511 0 .693-.677.25-.933l-1.214-.701a1 1 0 1 1 1-1.732l1.214.701c.443.256.939-.24.683-.683l-.701-1.214a1 1 0 0 1 1.732-1l.701 1.214c.256.443.933.261.933-.25V1a1 1 0 0 1 1-1Zm2 5a1 1 0 1 0-2 0 1 1 0 0 0 2 0ZM6 7a1 1 0 1 0-2 0 1 1 0 0 0 2 0Zm1 4a1 1 0 1 0 0-2 1 1 0 0 0 0 2Zm5-3a1 1 0 1 0-2 0 1 1 0 0 0 2 0Z" />
                </svg></a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#nav2">
                <div class="navbar-toggler-icon"></div>
            </button>
            <div class="collapse navbar-collapse" id="nav2">
                <ul class="navbar-nav">
                    <li class="nav-item">
                        <a href="index.html" class="nav-link">HOMEPAGE</a>
                    </li>
                    <li class="nav-item">
                        <a href="about.html" class="nav-link">RENCOFILSTAT</a>
                    </li>
                    <li class="nav-item">
                        <a href="article.html" class="nav-link active">NASH ARTICLES</a>
                    </li>
                </ul>
            </div>
        </div>
    </nav>
    <br>
    <!-- DIVIDER -->

    <div class="py-4">
        <div class="container">
            <div class="row g-4">

                <div class="col-md-4 col-sm-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/madrigal.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Pharmaceuticals Completes Submission of New Drug Application
                                Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver
                                Fibrosis.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/07/17/2705202/0/en/Madrigal-Pharmaceuticals-Completes-Submission-of-New-Drug-Application-Seeking-Accelerated-Approval-of-Resmetirom-for-the-Treatment-of-NASH-with-Liver-Fibrosis.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 17, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/akero.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Phase 2B SYMMETRY Cohort D Study Met Safety &
                                Tolerability Endpoints and Significantly Improved
                                Non-Invasive Markers of NASH-Related Disease.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/06/05/2681816/0/en/Akero-Therapeutics-Phase-2b-SYMMETRY-Cohort-D-Study-Met-Safety-Tolerability-Endpoints-and-Showed-Adding-EFX-to-GLP-1-Therapy-Significantly-Improved-Non-Invasive-Markers-of-NASH-Rel.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 5, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/viking.png" alt="" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Viking Therapeutics Announces Positive Top-Line Results from Phase 2b
                                VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-top-line-results-from-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-nash-301825395.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 16, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/madrigal.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Receives Breakthrough Therapy Designation from FDA for
                                Resmetirom.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-breakthrough-therapy-designation-fda"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">April 18, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/hepion.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Anti-Cancer Potential of Rencofilstat Expanded with Results from
                                Preclinical Multiple Myeloma Studies. lorem10</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2023/01/18/2591025/0/en/Anti-Cancer-Potential-of-Rencofilstat-Expanded-with-Results-from-Preclinical-Multiple-Myeloma-Studies.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 18, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/hepion.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Anti-Cancer Activity of Rencofilstat in Combination with Proteosome
                                Inhibitors</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/01/10/2586637/0/en/Presentation-of-Preclinical-Study-Highlighting-Anti-Cancer-Activity-of-Rencofilstat-in-Combination-with-Proteosome-Inhibitors.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 10, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/madrigal.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Announces Additional Positive Results from the Pivotal Phase 3
                                MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/01/06/2584391/0/en/Madrigal-Announces-Additional-Positive-Results-from-the-Pivotal-Phase-3-MAESTRO-NASH-Clinical-Trial-of-Resmetirom-for-the-Treatment-of-NASH-with-Liver-Fibrosis.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 6, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/madrigal.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Announces Positive Topline Results from the Pivotal Phase 3
                                MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2022/12/19/2576163/0/en/Madrigal-Announces-Positive-Topline-Results-from-the-Pivotal-Phase-3-MAESTRO-NASH-Clinical-Trial-of-Resmetirom-for-the-Treatment-of-NASH-and-Liver-Fibrosis.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 19, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/akero.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/12/08/2570081/0/en/Efruxifermin-Granted-FDA-Breakthrough-Therapy-Designation-for-NASH.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 8, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/akero.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics: Phase 2b HARMONY Study, 50mg and 28mg EFX Doses
                                Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24
                                Weeks.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/09/13/2514749/0/en/In-Akero-Therapeutics-Phase-2b-HARMONY-Study-Both-the-50mg-and-28mg-EFX-Doses-Achieved-Statistical-Significance-on-Primary-and-Secondary-Histology-Endpoints-after-24-Weeks.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 13, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/madrigal.png" class="img-fluid" alt="" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom
                                was
                                Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures
                                of
                                Liver and Cardiovascular Health.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/01/31/2375613/0/en/Positive-Topline-Phase-3-MAESTRO-NAFLD-1-Data-Demonstrate-Resmetirom-was-Safe-Well-Tolerated-and-Provided-Statistically-Significant-Improvements-in-Key-Measures-of-Liver-and-Cardio.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 31, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/hepion.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Rencofilstat in Combination with an Immune Checkpoint Inhibitor,
                                Demonstrates Synergistic Anti-Tumor Activity.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/01/26/2373431/0/en/Hepion-Pharmaceuticals-Rencofilstat-in-Combination-with-an-Immune-Checkpoint-Inhibitor-Demonstrates-Synergistic-Anti-Tumor-Activity-in-a-Nonclinical-Liver-Cancer-Study.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 26, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/hepion.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of
                                CRV431 in a Nonclinical Liver Cancer Study.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/11/16/2335363/0/en/Hepion-Pharmaceuticals-and-FibroFind-Announce-Anti-Cancer-Activity-of-CRV431-in-a-Nonclinical-Liver-Cancer-Study.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 16, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12 ">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="images/akero.png" class="img-fluid" alt="">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin
                                (EFX) for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/10/19/2316901/0/en/Akero-Therapeutics-Receives-FDA-Fast-Track-Designation-for-Efruxifermin-EFX-for-the-Treatment-of-NASH.html"
                                    class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">October 19, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

</body>

</html>